Clinical analysis of myelodysplastic syndrome/acute myeloid leuke-mia secondary to malignant tumors in 11 cases
10.3969/j.issn.1000-8179.20141533
- VernacularTitle:恶性实体瘤继发骨髓增生异常综合征急性髓系白血病11例分析
- Author:
Chanjuan LI
;
Haifeng ZHAO
;
Weipeng ZHAO
;
Qian LI
;
Zhigang ZHAO
;
Xiaofang WANG
;
Yong YU
;
Yafei WANG
;
Yizhuo ZHANG
- Publication Type:Journal Article
- Keywords:
myelodysplastic syndrome;
acute myeloid leukemia;
clinicopathological features;
etiology;
treatment
- From:
Chinese Journal of Clinical Oncology
2015;(7):373-377
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the etiology, clinical characteristics, and treatment of myelodysplastic syndrome/acute my-eloid leukemia (t-MDS/AML) secondary to malignant tumors. Methods: We retrospectively analyzed 11 patients with t-MDS/AML and investigated the treatment of primary tumors, clinical manifestations, treatment, and survival of t-MDS/AML patients. Results:A total of 11 patients were exposed to cytotoxic chemotherapeutic agents or radiation therapy for their primary tumors. The median laten-cy was 36 months. Common symptoms were fatigue, dyspnea, bleeding, and infection, all of which were related to deficits in hemato-poiesis. Therapeutic regimen included support therapy, immunomodulatory therapy, and chemotherapy. The median overall survival and disease-free survival periods were 28 months and 19 months, respectively, and the overall survival rate for 3 years was 44.4%. Conclu-sion:t-MDS/AML is a serious complication of chemotherapy or radiotherapy for a malignant or nonmalignant condition. The curative effect is limited, and prognosis is poor. Therefore, we should take t-MDS/AML into consideration when making treatment plans for can-cer patients to evaluate treatment benefits and to avoid treatment-related complications.
